HIV Biology and Pathogenesis {#Sec1}
============================

Human immunodeficiency virus type 1 (HIV-1) principally infects a subgroup of immune cells called activated CD4^+^ lymphocytes, and secondarily infects macrophages, also a cellular component of the immune system. While infected macrophages are far fewer in number than lymphocytes, they are believed to be particularly important in the central nervous system (CNS). Mature viral particles feature a glycoprotein coat, or envelope, that allows them to identify, attach to, and enter these specific cell types.

At the earliest stage of its life cycle after infecting CD4^+^ lymphocytes and macrophages, HIV directs these host cells to manufacture a viral enzyme, reverse transcriptase, which then converts viral RNA into DNA for insertion into the host cell's genetic library. HIV has no proofreading enzymes to correct for RNA to DNA conversion errors, leading to frequent DNA base substitutions and rapid genetic mutation. This propensity for copying errors is a major reason that HIV frequently develops resistance to therapy (see below). Furthermore, the fact that HIV DNA resides dormant, or replicatively inactive, in many cells protects it from detection by the immune system, making eradication of infection impossible even with the best available therapies.

HIV causes CNS disease in two general ways. Primary HIV CNS diseases are those for which the virus is both necessary and sufficient, while secondary CNS diseases require another, opportunistic pathogen that takes advantage of progressive immune deficiency. Although there is abundant evidence of primary HIV CNS injury, the virus does not directly infect neurons, and instead causes neuronal damage indirectly by infecting macrophages and other cells in the CNS.

Disease Staging {#Sec2}
===============

The clinical course of untreated HIV infection proceeds through four stages, which may or may not be apparent to patients themselves. The first stage is characterized by asymptomatic incubation lasting 2--4 weeks, followed by a symptomatic acute infection stage lasting 4 weeks on average (Kahn and Walker [@CR27]). The symptoms of acute HIV infection are quite similar to those of many other viral infections, and therefore may pass without detection of HIV. Next follows a relatively silent period of ongoing viral replication and immune destruction known as the latency stage (Gottlieb et al. [@CR21]). Its duration varies significantly, lasting anywhere from weeks to over a decade. During this time, patients may feel relatively well, again masking detection of the virus.

Left untreated, however, HIV almost always causes progressive immune system destruction, evidenced by drops in the numbers of CD4^+^ and CD8^+^ T cells (Laurence [@CR33]). The result is acquired immune deficiency syndrome (AIDS), which is characterized by susceptibility to various opportunistic infections. AIDS is diagnosed when the immune system composition is altered below a threshold percentage or when T cell quantity is too low. According to the Centers for Disease Control's (CDC) 1993 standards, an HIV-infected individual has AIDS when either (a) their CD4^+^ cells fall to fourteen percent or less of total lymphocytes, or (b) when the CD4^+^ count is less than 200 cells/µL or (c) when at least one of a specific set of opportunistic infections or neoplasms occurs (Centers for Disease Control and Prevention [@CR9]). Current HIV treatment guidelines suggest starting combination antiretroviral therapy (cART) only in patients with advanced disease as defined by specific criteria that are revised on an annual basis (Hammer et al. [@CR23]).

HIV replication is measured by quantifying the viral load, defined as the number of viral RNA copies per milliliter of blood plasma. Patients who maintain good adherence to cART often achieve reduction of the viral load to undetectable levels, curbing the destruction of CD4^+^ T lymphocytes (Gulick et al. [@CR22]), but not eradicating the virus which reemerges in nearly all patients when cART is stopped. As these lymphocytes repopulate their numbers, the immune system regains strength. Thus cART frequently results in substantial immune reconstitution in HIV-infected individuals (Palella et al. [@CR49]).

Antiretroviral Therapy {#Sec3}
======================

Since 1996, cART---also known as highly active antiretroviral therapy, or HAART---has produced dramatic improvements in health and longevity for HIV-infected individuals (Palella et al. [@CR49]). cART options usually consist of three medications representing at least two different classes of antiretroviral drugs (see below). Multiple drugs from different classes are required because new mutations---including those that confer resistance to single drug or classes---arise at staggering rates. By inhibiting HIV replication at several stages in the viral life cycle, cART markedly reduces the likelihood that drug resistance will develop.

cART regimens typically include two nucleoside (or nucleotide) analogue reverse transcriptase inhibitors (NRTIs) and either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI). NRTIs and NNRTIs both interfere with reverse transcriptase function, preventing new viral particles from being formed. Nucleoside RTIs differ from their non-nucleoside counterparts in how they are designed to interfere with HIV reverse transcriptase. NRTIs interact with the chemically active binding site to prevent enzyme activity. However, NNRTIs bind to an allosteric regulation site, altering the transcriptase enzyme's shape and function. Protease inhibitors, the third component to most cART regimens, prevent the processing of manufactured viral particles through inhibition of HIV protease. Other classes of antiretroviral drugs include the integrase enzyme inhibitors, viral entry (fusion) inhibitors, and HIV maturation inhibitors. A regimen commonly prescribed to naïve patients is efavirenz (an NNRTI) plus tenofovir and emtricitabine (NRTIs) coformulated as a single pill given once a day, known as atripla.

Judicious use of antiretroviral therapy, by suppressing viral replication and partially restoring immune function, can prevent opportunistic infections and markedly prolong survival with HIV. As a result, most HIV brain disorders in the developed world today result not from opportunistic infections, but from primary HIV disease of the nervous system (Langford et al. [@CR31]).

HIV Epidemiology {#Sec4}
================

According to estimates from the 2008 UNAIDS report on the global AIDS epidemic, there were approximately 33.2 million people living with HIV worldwide at the end of 2007 (Joint United Nations Programme on HIV/AIDS \[UNAIDS\] [@CR65]). As prevention and treatment services have become more accessible, HIV-related deaths have declined---in 2007 there were 2.1 million HIV-related deaths worldwide, compared to 3.1 million in 2005 (UNAIDS [@CR65]). These improvements in incidence and mortality have not been consistent throughout the world, occurring principally in developed countries. Although the HIV epidemic has stabilized somewhat since 2000---in that the annual number of new HIV infections has declined from approximately 3.0 million in 2001 to 2.7 million in 2007---the overall number of people living with HIV has steadily increased because new infections occur each year, and HIV treatment prolongs survival (UNAIDS [@CR65]).

While the majority of HIV research has taken place in Western countries, the virus itself is most prevalent and least-controlled in resource-limited settings such as sub-Saharan Africa and South and Southeast Asia (Centers for Disease Control and Prevention [@CR11]; Sotrel and Dal Canto [@CR56]). Although sub-Saharan Africa accounts for just over 10% of the world's population, the number of people living with HIV in this region at the end of 2007 was approximately 22 million, making sub-Saharan Africa home to 67% of all people living with HIV (UNAIDS [@CR64]). AIDS remains the leading cause of death in this region, with 76% of all HIV-related deaths in 2007 occurring here (McCutchan [@CR43]). In the same year, it is estimated that out of the 2.7 million new HIV infections worldwide, almost two thirds occurred in sub-Saharan Africa (UNAIDS [@CR64]).

In Asia the number of people living with HIV at the end of 2007 was around 5.0 million, with the highest and fastest growing HIV infection levels concentrating in Southeast Asia (Centers for Disease Control and Prevention [@CR10]). Epidemics in Indonesia, Pakistan, and Viet Nam are soaring. In Viet Nam alone, between 2000 and 2005, the number of people living with HIV more than doubled (UNAIDS [@CR64]). Although sub-Saharan Africa remains the most seriously affected region by the AIDS epidemic, the most concerning increases in the incidence of new HIV infections are occurring in Eastern Europe and Central Asia. In this region, an estimated 1.6 million people were living with HIV at the end of 2007, an increase in prevalence of 150% since 2002 (UNAIDS [@CR64]). Worst affected are Russia and Ukraine, with 62% of infections attributable to intravenous drug use (UNAIDS [@CR65]).

In North America and Western and Central Europe there were approximately 2.0 million people living with HIV at the end of 2007---the United States accounting for an estimated 1.2 million of these (UNAIDS [@CR65]).

Women account for half of all people living with HIV worldwide---at the end of 2007 an estimated 15.4 million women were infected with HIV (UNAIDS [@CR65]). The proportion of women living with HIV varies significantly between different regions of the world, with a higher burden in sub-Saharan Africa and the Caribbean. For example, in sub-Saharan Africa women comprise nearly 61% of all adults living with HIV, while in the United States only 25% of people living with HIV are women (Centers for Disease Control and Prevention [@CR10]; UNAIDS [@CR64]). Over the last 10 years, the number of women living with HIV globally has remained stable, but in Latin America, Asia, and Eastern Europe this number is slowly increasing as they are infected by their male partners who are likely to have been infected through injecting drug use, or unprotected sex (UNAIDS [@CR64]). In addition to the direct impact that HIV has on these women, there is also a known risk of mother-to-child transmission.

HIV Subtypes {#Sec5}
============

HIV infections worldwide are characterized according to subtypes (clades), reflecting variants that are genetically more related to one another and often cluster in geographic regions because of founder effects. The high overall genetic diversity that characterizes HIV has been a key factor in its worldwide spread, and poses concerns for disease progression, as well as diagnosis, treatment and prevention efforts (Hemelaar et al. [@CR24]). Findings from studies conducted in Western countries derive mainly from work on HIV-1 clade B infection in Caucasian populations, and therefore may not be generalizable to HIV clades and human populations globally. HIV-1 clade B is responsible for only 10% of infections worldwide and predominates in Western Europe, Australia, and the Americas (McCutchan [@CR43]). In the United States, HIV-1 clade B represents the vast majority of infections (98%) with only minor contributions by other clades (Hemelaar et al.). However, in sub-Saharan Africa---the region most affected by the HIV epidemic---HIV-1 clade C is most common, accounting for about 50% of infections worldwide. In other areas heavily affected by the HIV epidemic, such as South and Southeast Asia, the predominant subtype is HIV-1 Clade AE. Finally, in Eastern Europe, Russia, and populous areas of Asia where the epidemic is rapidly expanding, 79% of infections are caused by HIV-1 clade A (Hemelaar et al.).

The effects of HIV subtypes, or clades, on disease progression and treatment remain unclear (Liner et al. [@CR37]). While numerous studies indicate that reverse transcriptase inhibitors and protease inhibitors are equally effective treating all HIV subtypes (Alexander et al. [@CR1]; Bocket et al. [@CR7]; Pillay et al. [@CR52]), other studies claim that different HIV subtypes are more efficient in developing antiretroviral resistance, and present diminished drug sensitivity and HIV pathogenicity (Eshleman et al. [@CR17]; Kantor et al. [@CR28]; Spira et al. [@CR57]).

Mechanisms of HIV-Associated Injury {#Sec6}
===================================

HIV infection results in disruption of neuronal function by a variety of mechanisms that can be grouped into three general categories: viral factors, host factors and co-factors. Viral factors derive from the virus itself, and include several proteins encoded by the viral genome. Host factors, on the other hand, evolve indirectly or secondarily from infection, but may damage even uninfected cells such as neurons. Co-factors are social or behavioral characteristics or co-morbid conditions that may contribute to or amplify the pathogenicity of HIV. In the nervous system, these factors converge in producing damage to the elaborate network of connections between neurons that take place at dendrites and synapses. This synaptodendritic injury, described in detail below, disrupts the highly integrated functioning of neural systems that is required to process information, leading to HIV-associated neurocognitive disorders (HAND). As discussed in more detail in other manuscripts in this series, HIV associated dementia (HAD) is the most severe form of HAND. The brain, however, does not respond passively to synaptodendritic injury, but instead actively upregulates pathways promoting repair and regeneration. These pathways have become particularly important today, as survival has been prolonged by cART. Because both viral and host factors play a role in HAND, effective treatment might require both cART and so-called "adjunctive" therapies that include neuroprotective and neuroregenerative agents.

**Neurotoxic Viral Factors** The HIV genome codes for a variety of proteins that can damage neuronal cells and interfere with CNS function. Two of the more important viral proteins shown to be neurotoxic are gp120, the virus's envelope protein, and transactivator of transcription (Tat). gp120 is necessary for infectivity, but also interacts with host cellular receptors to alter glutamate pathway signaling and induce cytokine production that can injure neurons and affect the activation state of microglia and astrocytes. Patterns of neuronal injury seen in the brains of cognitively impaired HIV-infected individuals that come to autopsy can be replicated in cultures of human nervous tissue exposed to gp120 (Iskander et al. [@CR26]) and in transgenic mice that express HIV-1 gp120 in the brain (Toggas et al. [@CR60]). These changes include synaptodendritic injury, reactive astrocytosis, and microgliosis, and loss of large pyramidal neurons (Kaul and Lipton [@CR29]). One molecular mechanism by which gp120 might induce these changes is through glutamate-mediated excitotoxicity, which can initiate caspase cascades (Tenneti and Lipton [@CR59]).Another viral protein reported to cause neuronal injury is Tat, which is produced by infected astrocytes (Nath [@CR46]). In experiments in which Tat-expressing astrocytes were injected into the rat dentate gyrus, Tat was taken up by granule cells and transported along neuronal pathways to the CA3 region of the hippocampus, where it caused glial cell activation and neurotoxicity (Bruce-Keller et al. [@CR8]). HIV Tat can cause mitochondrial dysfunction, dendritic loss, and cell death in neurons at concentrations lower than those needed to support viral replication (Chauhan et al. [@CR12]).

**Neurotoxic Host Factors** Secondary effects of HIV infection on the immune system can amplify nervous system damage. Many of the host factors relevant to HIV CNS injury are chemical mediators of inflammation and immunity---cytokines and chemokines. Cytokines are produced by immune cells including macrophages that traffic into the CNS from the peripheral circulation, as well as by brain astrocytes and microglia activated or infected by HIV. Chemokines represent a subset of cytokines with chemo-attractant properties, and are particularly important in HIV-related pathology. Chemokine receptors are distributed throughout the brain on microglia, astrocytes, oligodendrocytes and neurons.Abnormal activation of cytokine and chemokine receptors results in ultrastructural and functional neuronal alterations that are at least partially reversible. This suggests that appropriate treatments might enhance neuronal repair and ameliorate the damage arising from abnormal activation of cytokine or chemokine receptors. Importantly, host factors can differ between individuals. For example, increased susceptibility to neurodegeneration in HIV is associated with host genetic variations that might account for differential susceptibility to HAND between different individuals infected with the same viral strain (Gonzalez et al. [@CR20]; Quasney et al. [@CR53]).

**Cofactors in CNS Injury** HIV-infected individuals frequently have co-morbidities such as abuse of drugs and alcohol or infection with viral co-pathogens such as hepatitis C virus (HCV). These cofactors may contribute to CNS injury. For example, in neuropathological studies, HIV-infected individuals dying with histories of injection drug use show more activated microglia and diffuse astrogliosis in the white matter of the brain than their HIV-infected non-addicted counterparts (Cook et al. [@CR15]; Persidsky et al. [@CR50]; Langford et al. [@CR31]) found that those dying with HIV and a history of methamphetamine addiction had greater loss of calbindin-immunostaining interneurons than in those with either condition alone. In vitro studies (Bagasra et al. [@CR5]) as well as studies with rhesus monkeys (Tyor and Middaugh [@CR63]) and mice (Winsauer et al. [@CR66]) suggest that alcohol may exacerbate the immunological abnormalities associated with HIV infection, specifically the peripheral immune system. In addition, several studies have demonstrated that HCV co-infection was associated with a greater risk of neurocognitive disorders among those with HIV, with or without drug use (Cherner et al. [@CR14]; Morgello et al. [@CR45]). Because HCV is also associated with systemic and possibly CNS immune activation, it is possible that there may be some common immuno-neuropathogenic mechanisms leading to a heightened likelihood of CNS disease in co-infected individuals.

HIV-Associated Synaptodendritic Injury {#Sec7}
======================================

Synaptodendritic injury is a general term encompassing a variety of structural and chemical changes that ultimately can impair the normal functioning of neuronal networks. Normal synaptodendritic networks are complex and highly branching, whereas injured networks are simplified. Features of syndaptodendritic injury include dendritic spine retraction, beading and aberrant sprouting. Higher cognitive functions depend on the integrity of complex synaptodendritic networks, therefore damage results in deficient cognitive skills and behavior.

Synaptodendritic injury is demonstrated by immunostaining with antibodies to presynaptic synaptophysin (SYN) and postsynaptic microtubule associated protein-2 (MAP2) (Orenstein et al. [@CR48]). MAP2 is expressed on neuronal cell bodies and dendrites. In HIV-infected individuals, the degree of neurocognitive impairment is strongly related to loss of immunostaining for SYN and MAP2 (Moore et al. [@CR44]). This technique has provided evidence that the striatum and the hippocampus are particularly affected (Bruce-Keller et al. [@CR8]; Moore et al. [@CR44]). This regional vulnerability parallels the higher burden of HIV proteins and viral RNA in the striatum and white matter connecting the striatum to the prefrontal cortex (Masliah et al. [@CR40]).

Techniques for measuring synaptodendritic injury in living humans are indirect and imprecise. Proteins released from damaged neurons into the extracellular space can be detected in the cerebrospinal fluid (CSF) or blood. Elevated CSF neurofilament protein (NFL) concentrations, for example, are thought to reflect injury to myelinated axons. CSF NFL levels are increased both in the context of HIV dementia (Arnold [@CR4]; Law et al. [@CR34]) and after the interruption of cART, which results in a significant rebound of HIV replication. However, it is not known whether increased NFL can result from neuronal injury alone or requires cell death, and there are no data on the dynamic relationship between changes in neurological status in HIV patients and changes in NFL levels.

It is reasonable to propose that synaptodendritic loss will reduce the overall volume of brain gray and white matter. Gross structural atrophy can be visualized by brain computed tomography (CT) and magnetic resonance imaging (MRI), and careful radiological-neuropathological correlation studies have shown that white matter loss and abnormal white matter signal are closely correlated with the loss of MAP-2 immunostaining, particularly in the presence of HIV encephalitis (Archibald et al. [@CR3]). Worsening white matter abnormalities correlate with worsening cognitive impairment (Everall et al. [@CR18]).

Nervous System Repair {#Sec8}
=====================

Synaptic dendritic networks in the healthy brain undergo continuous remodeling, reflecting plasticity, which can include increased dendritic branching, augmentation of axonal collaterals, generation of new synaptic connections and activity-dependent modification of existing synapses (Makrigeorgi-Butera et al. [@CR39]). Various mediators of CNS plasticity may include brain derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), acidic fibroblast growth factor (aFGF, FGF1), macrophage inflammatory protein-2 (MIP2), stromal-derived factor-1alpha (SDF-1α) and leptin (Isackson [@CR25]; Pezet and Malcangio [@CR51]; Shanley et al. [@CR55]). Neurogenesis may also participate in restoration of function after brain injury (Langford et al. [@CR30]; Tomlinson et al. [@CR62]).

HIV-Associated Neurocognitive Disorders {#Sec9}
=======================================

Neurodegeneration and synaptodendritic injury in HIV-infected individuals result in the clinical syndromes of HAND. Neurocognitive disorders can range in severity from slight deficits to debilitating dementia. In 2007 the National Institute of Mental Health (NIMH) and the National Institute of Neurological Diseases and Stroke (NINDS), commissioned the development of updated, working research criteria for HAND, based on criteria proposed by the San Diego HIV Neurobehavioral Research Center (HNRC). The resulting criteria defined three conditions: asymptomatic neurocognitive impairment (ANI), HIV-associated mild neurocognitive disorder (MND), and HIV-associated dementia (HAD) (Antinori et al. [@CR2]). ANI describes individuals with usually mild impairment in two or more cognitive areas, demonstrated by neuropsychological testing, without a clear effect on everyday functioning. MND refers to the presence of mild to moderate deficits in two or more cognitive areas which create at least mild interference in everyday functioning. Finally, HAD describes individuals with documented moderate to severe deficits in two or more cognitive areas, with substantial impairment in every day functioning making the person incapable of employment and often unable to live independently.

Since the introduction of cART in 1996, the incidence of HAD, the more severe form of HAND, has decreased (McArthur [@CR41]; McArthur et al. [@CR42]). Despite this, the overall prevalence of HAND has not declined, possibly because HIV infected individuals with milder neurocognitive disorders are living longer, or because cART is not as effective in the brain as in the periphery. Thus milder impairments persist in many patients, with prevalence ranging between 30% and 50% depending in part upon disease stage, as documented in several reports in this volume.

Treatment of HAND {#Sec10}
=================

The notion that cART might not be as effective in the brain as it is systemically derives from the observation that the blood brain barrier (BBB) frequently limits the movement of antiretrovirals from the circulation into the CNS. Several factors affect the CNS penetration of antiretroviral medications. Tight junctions between brain endothelial cells prevent the diffusion of polar molecules, making non-polarity (lipophilicity) an important determinant of CNS penetration (Strazielle and Ghersi-Egea [@CR58]). Highly protein-bound drugs have lower unbound concentrations, so fewer drug molecules are available to cross the BBB (Langford et al. [@CR32]; Wynn et al. [@CR68]). Once a drug does cross the BBB, efflux transporters---cellular proteins that pump various molecular substrates---may then promptly push it back into the circulation. As a result, HIV replication may persist in the CNS, despite adequate peripheral suppression (Blankson et al. [@CR6]; De Luca et al. [@CR16]; Wong et al. [@CR67]).

The degree of penetration of antiretroviral therapy into the CNS seems to influence the extent of neurocognitive improvement, with individuals on regimens containing more CNS-penetrating drugs presenting better CSF viral load suppression (Letendre et al. [@CR35]). Also, optimal antiretroviral concentrations in the CNS may be necessary to limit local HIV replication and prevent the development of drug-resistant viral strains in the CSF, which have the potential to re-infect the periphery (Reddy et al. [@CR54]). Studies are ongoing to address the question of whether choosing antiretrovirals with greater CNS penetration will improve neurocognitive outcomes in HAND.

Beyond antiretroviral therapy, there is considerable interest in treating HAND with agents that promote neuronal repair or prevent further injury, so-called neuroprotective or regenerative therapies. For example, lithium, which is used to treat bipolar disorder, also modulates the expression of the pro-apoptotic glycogen synthase kinase 3β (GSK3β). In vitro, lithium prevents the induction of dendritic spine loss and simplification by HIV gp120 (Everall et al. [@CR19]), indicating that it might be useful in HIV. In humans with HAND, lithium administration was associated with improved neurocognitive performance in a single-arm, 12-week study (Letendre et al. [@CR36]). Minocycline is an antibiotic that has anti-inflammatory and neuroprotective effects that are currently being studied in humans. Memantine, a non-competitive antagonist of the NMDA receptor, prevents Tat and gp120-induced intracellular calcium increases and glutamate toxicity (Chen et al. [@CR13]; Lipton and Chen [@CR38]; Nath et al. [@CR47]; Toggas et al. [@CR61]). Early clinical trials suggest that some of these agents may have benefits, but none has been subjected to rigorous scientific evaluation in large, phase III licensing studies.

Summary and Conclusions {#Sec11}
=======================

Understanding central nervous system injury in HIV infection requires an appreciation of some of the complexities of disease progression and its treatment. The outlook for patients with HIV has improved dramatically as increasingly effective antiretroviral therapies have become available. Nevertheless, neurocognitive impairment remains quite prevalent and is associated with reduced quality of life and social and occupational disabilities. Since HIV, with treatment, has become a chronic, manageable disease, the neurocognitive aspects of this condition should become an important focus for future research on pathogenesis and treatment.
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